Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Arch Biopartners Inc V.ARCH

Alternate Symbol(s):  ACHFF

Arch Biopartners Inc. is a late-stage clinical trial company focused on preventing acute kidney injury. The Company is developing a platform of new drugs to prevent inflammation injury in the kidneys, lungs and liver via the dipeptidase-1 (DPEP1) pathway and are relevant for many common injuries and diseases where organ inflammation is an unmet problem. The Company’s lead drug candidate is LSALT Peptide. The Company is engaged in the clinical development of LSALT Peptide and other DPEP-1 targeting drug candidates for indications where inflammation of the lungs, liver and kidneys is an unmet problem. LSALT Peptide is in a second phase II trial, targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). The Company has additional technology platforms in its portfolio, which are AB569 and Borg. AB569 is an anti-infective candidate for treating or preventing antibiotic resistant bacterial infections, primarily as a topical treatment for wounds.


TSXV:ARCH - Post by User

Comment by SrPlataon Nov 25, 2021 5:41pm
114 Views
Post# 34166717

RE:New High

RE:New HighYes you are right, trading pattern was different today. Just remember tommorow US markets close 3 hourrs  early 1:00 EST. BTW there will be no Black Friday discounts on ARCH stock tomorrow. Thanks for the info on TSXV margin requirements, I am more familiar with the US margin requiremnts.

I agree stock is still super cheap, i bot more yesterday at $3.41 USD that is the highest price I have paid and it took a while for my limit order to get filled BTW lowest price I bot was .99 USD and avg $1.50 started buying in June 2021, after a friend asked me to chedk out ARCH. The more I researched and really dug into the company and the way they were financing their growth and stages of development the more I bought. When I really understood that management was on the side of the shareholders and were the largest holders of the stock the more I bought. When I really got my head around the potential market size the more I bought. When I realized they got as far as they have in a Phase 2 trial without the Wall Street sharks raising money for them with warrants attached, the more I bought. 

Happy Thanksgiving to all and especially my friend who asked me to check out ARCH



<< Previous
Bullboard Posts
Next >>